following BRAF(V600) inhibitor therapy. Conclusions: GSK2118436 treatment results in no detectable negative impact on existing systemic immunity or the de novo generation of tumor-specific...
이 논문을 인용한 문헌 (6) ; Plachouri, Kerasia-Maria ; Florou, Vaia ; Georgiou, Vasileios ; Georgiou, Sophia 2023 "Cutaneous Side Effects of Modern Targeted Therapy and Immunotherapy in Patients with Dermatological Malignancies" Cancers, 15(12): 3126~ · 상세보기 ; Boada, Aram 2015 "Toxicidad cutánea de los inhibidores del BRAF y del MEK" Piel, 30(5): 309~315 · 상세보기 ; Fernandez-Flores, Angel 2016 "Lesions With an Epidermal Hyperplastic Pattern: Morphologic Clues in the Differential Diagnosis" The American Journal of derma ...
다른 한편으로 돌연변이가 일어난 단백질이 새로운 기능을 얻거나(gain of function) 활성화될 수도 있다. 예를 들어 BRAF 유전자에서 돌연변이로 인해 발린이 글루탐산으로 바뀌면 RAF 단백질이 활성화되는데, 이는 암세포에서 증식 신호의 무제한 발생을 유도한다
Omipalisib (GSK2126458) is an orally active and highly selective inhibitor of PI3K with Kis of 0.019 nM/0.13 nM/0.024 nM/0.06 nM and 0.18 nM/0.3 nM for p110α/β/δ/γ, mTORC1/2, respectively. Omipalis...
Phase III, randomized, open-label, multicenter trial (BREAK-3) comparing the BRAF kinase inhibitor dabrafenib (GSK2118436) with dacarbazine (DTIC) in patients with BRAFV600E-mutated...
단체 : 1Department of Dermatology, Westmead Hospital, Sydney, New South Wales, Australia 2Department of Medical Oncology, Westmead Hospital, Sydney, New South Wales, Australia 3Faculty of Medicine, University of Sydney, Sydney, New South Wales, Australia 4Melanoma Institute of Australia and University of Sydney at Westmead Hospital, Westmead, New South Wales, Australia 5Cancer Institute NSW, Sydney, New South Wales, Australia 6Department of Tissue Pathology, Westmead Hospital, Sydney, New South Wales, Australia 7Faculty of Medicine, Universit ...
Single-agent BRAF inhibitor therapy is associated with high rates of resistance and the development of secondary cutaneous malignancies, owing to paradoxical MAPK pathway activation in skin...
bRaf complexed with an inhibitor
PurposeDabrafenib (GSK2118436) is a potent inhibitor of mutated BRAF kinase. Our multicenter, single-arm, phase II study assessed the safety and clinical activity of dabrafenib in BRAFV600E/K mutat...
Trametinib (GSK1120212), FDA-approved to treat BRAF-mutated melanoma. Also studied in combination with BRAF inhibitor dabrafenib to treat BRAF-mutated melanoma. In...